Show simple item record

dc.contributor.authorMortezagholi, S
dc.contributor.authorBabaloo, Z
dc.contributor.authorRahimzadeh, P
dc.contributor.authorNamdari, H
dc.contributor.authorGhaedi, M
dc.contributor.authorGharibdoost, F
dc.contributor.authorMirzaei, R
dc.contributor.authorBidad, K
dc.contributor.authorSalehi, E
dc.date.accessioned2018-08-26T08:54:50Z
dc.date.available2018-08-26T08:54:50Z
dc.date.issued2017
dc.identifier.urihttp://dspace.tbzmed.ac.ir:8080/xmlui/handle/123456789/54207
dc.description.abstractContext: Systemic lupus erythematosus (SLE) is a systemic autoimmune disease characterized by autoreactive antibodies. Recent findings revealed the importance of innate immune responses, especially Toll-like receptors (TLRs) in the pathogenesis of SLE. Objective: In this study, the level of TLR9 expression on peripheral blood mononuclear cells (PBMCs) was analyzed. The levels of produced IFN-? were also measured in supernatant of PBMCs from SLE patients and healthy controls after stimulation with CpG ODN2216 which is a plasmocytoid dendritic cell (pDC)-specific TLR9 ligand. Materials and methods: TLR9 expression was analyzed by real-time polymerase chain reaction (PCR) and flow cytometry in 35 SLE patients and 38 healthy controls and IFN-? concentration was measured in supernatants using enzyme-linked immunosorbent assay (ELISA). Results: The results showed that the TLR9 expression in the mRNA and the protein level was significantly higher in PBMCs from SLE patients. However, IFN-? concentration in patients and controls significantly increased in response to CpG stimulation but this increase was significantly higher in healthy controls compared with SLE patients. Our results do not show any association between taking hydroxychloroquine and reduction in IFN-? production in SLE patients. Discussion and conclusions: Regarding the findings of the study, there is the possibility that TLR9 has played a role in SLE pathogenesis, and consequently it implies that TLRs can be considered to be the therapeutic targets for systemic autoimmunity. We may conclude that PBMCs in patients are functionally impaired in response to TLR ligation via innate response stimulating pathogen-associated molecular patterns (PAMPs). آ© 2016 Informa UK Limited, trading as Taylor & Francis Group.
dc.language.isoEnglish
dc.relation.ispartofImmunopharmacology and Immunotoxicology
dc.subjectalpha interferon
dc.subjectCpG odn2216
dc.subjectCpG oligodeoxynucleotide
dc.subjecthydroxychloroquine
dc.subjectmessenger RNA
dc.subjectprednisolone
dc.subjectprotein
dc.subjecttoll like receptor 9
dc.subjecttoll like receptor agonist
dc.subjectunclassified drug
dc.subjectalpha interferon
dc.subjectCpG ODN 2216
dc.subjectoligodeoxyribonucleotide
dc.subjectTLR9 protein, human
dc.subjecttoll like receptor 9
dc.subjectadult
dc.subjectaged
dc.subjectArticle
dc.subjectclinical article
dc.subjectcontrolled study
dc.subjectcytokine production
dc.subjectdendritic cell
dc.subjectdisease activity
dc.subjectdrug mechanism
dc.subjectenzyme linked immunosorbent assay
dc.subjectfemale
dc.subjectflow cytometry
dc.subjecthistopathology
dc.subjecthuman
dc.subjecthuman cell
dc.subjectimmunostimulation
dc.subjectin vitro study
dc.subjectin vivo study
dc.subjectligation
dc.subjectmale
dc.subjectperipheral blood mononuclear cell
dc.subjectplasma cell
dc.subjectpriority journal
dc.subjectprotein expression
dc.subjectreal time polymerase chain reaction
dc.subjectsupernatant
dc.subjectsystemic lupus erythematosus
dc.subjectdrug effects
dc.subjectgene expression regulation
dc.subjectimmunology
dc.subjectmiddle aged
dc.subjectmononuclear cell
dc.subjectpathology
dc.subjectsystemic lupus erythematosus
dc.subjectAdult
dc.subjectAged
dc.subjectFemale
dc.subjectGene Expression Regulation
dc.subjectHumans
dc.subjectInterferon-alpha
dc.subjectLeukocytes, Mononuclear
dc.subjectLupus Erythematosus, Systemic
dc.subjectMale
dc.subjectMiddle Aged
dc.subjectOligodeoxyribonucleotides
dc.subjectToll-Like Receptor 9
dc.titleEvaluation of TLR9 expression on PBMCs and CpG ODN-TLR9 ligation on IFN-? production in SLE patients
dc.typeReview
dc.citation.volume39
dc.citation.issue1
dc.citation.spage11
dc.citation.epage18
dc.citation.indexScopus
dc.identifier.DOIhttps://doi.org/10.1080/08923973.2016.1263859


Files in this item

FilesSizeFormatView

There are no files associated with this item.

This item appears in the following Collection(s)

Show simple item record